abstract |
The present invention relates to stable aqueous antibody formulations. In some embodiments, a stable aqueous formulation comprises about 2 mg / ml to about 100 mg / ml anti-IL5R antibody, and about 0.002% to about 0.01% polysorbate-20. Methods of making and using such antibody formulations are also provided. |